Skip to content
OpenCapital
Get started

BioLife Solutions BLFS Amortized cost of available-for-sale debt securities, current

Amortized cost of available-for-sale debt securities, current at other companies

GitLab logo
GitLabGTLB
$619.16M-1.8%
Eastern Bankshares, Inc. logo
Eastern Bankshares, Inc.EBC
$96.34M+68.6%
Dolby Laboratories, Inc. logo
Dolby Laboratories, Inc.DLB
$1.29M+132%
Independent Bank Corporation logo
Independent Bank CorporationIBCP
$24.56M-28.6%
ASI
Ategrity Specialty Insurance Company HoldingsASIC
$574.08M—
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$391.01M+24.4%

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02—

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%—
Operating margin-16.7%—
Net margin-68.7%—
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0×0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's amortized cost of available-for-sale debt securities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's amortized cost of available-for-sale debt securities, current?
BioLife Solutions (BLFS) reported amortized cost of available-for-sale debt securities, current of $58.2M in Q1 2026.
How has BioLife Solutions's amortized cost of available-for-sale debt securities, current changed year-over-year?
BioLife Solutions's amortized cost of available-for-sale debt securities, current increased by 169.2% year-over-year, from $21.62M to $58.2M.
What is the long-term trend for BioLife Solutions's amortized cost of available-for-sale debt securities, current?
Over 3 years (2022 to 2025), BioLife Solutions's amortized cost of available-for-sale debt securities, current has grown at a 8.8% compound annual growth rate (CAGR), from $43.31M to $55.8M.